Evidence map›Paper›PMID 42807196›Full record

ArticleFrontiers in immunology2026

Astragalus polysaccharide antagonized anti PD-1 efficacy in melanoma through inhibiting JAK-STAT1/CIITA and TLR/NF-κB signaling.

Ruilong Wang, Qiao Li, Mengguo Liu, Jinshu Yu, Min Peng, Xiaohong Deng, Rui Lei, Xiao Liu, Zhihao Li, Hiochon Leong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruilong Wang *Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Qiao Li *Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Mengguo Liu *Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Jinshu YuDepartment of Dermatology, Nantong Haimen People's Hospital, Nantong, China.
Min PengDepartment of Dermatology, Chuxiong Autonomous Prefecture Hospital of Traditional Chinese Medicine, Chuxiong, China.
Xiaohong DengDepartment of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Rui LeiDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Xiao LiuDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Zhihao LiSuzhou Medical College of Soochow University, Suzhou, China.
Hiochon LeongDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Jie RenDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Jinfeng WuDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Advanced melanoma remains a major clinical challenge due to resistance to immune checkpoint inhibitors (ICIs, e.g., anti PD-1). Astragalus Polysaccharide (APS) is a clinically approved immunomodulator for cancer treatment. However, its interaction with anti PD-1 remains largely unknown. This study aims to explore the efficacy and underlying mechanism of APS combined with anti PD-1 in melanoma. Methods: For Results: Unexpectedly, APS significantly antagonized the anti-tumor efficacy of anti PD-1 in melanoma mice. APS reversed anti PD-1-induced infiltration of CD4 Conclusion: APS antagonized anti PD-1 efficacy by inducing an immunosuppressive microenvironment via dual inhibition of JAK-STAT1/CIITA signaling and TLR/NF-κB signaling. This study suggests that the combination of natural polysaccharides and ICIs may warrant caution, although further studies are needed to validate these findings and determine their clinical relevance.

Indexed as

Astragalus PlantImmune Checkpoint InhibitorsMelanoma, ExperimentalPolysaccharidesProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorDendritic CellsJanus KinasesMiceMice, Inbred C57BLNF-kappa BSignal TransductionSTAT1 Transcription FactorToll-Like ReceptorsTumor MicroenvironmentImmune Checkpoint InhibitorsJanus KinasesNF-kappa BPdcd1 protein, mousePolysaccharidesProgrammed Cell Death 1 ReceptorStat1 protein, mouseSTAT1 Transcription FactorToll-Like Receptorsanti PD-1astragalus polysaccharideJAK-STAT1melanomaTLR

Identifiers

PMID42807196
PMCPMC13616731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.